Cyclophosphamid clinical trials
Cyclophosphamid is named as an intervention in 10 current clinical trials in our China, Germany, France, Spain, Italy, Sweden, Denmark, Switzerland, Czechia, Belgium, UK, Turkey, Netherlands, Austria, Norway, Australia and Israel registers. 9 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is Essen Biotech (2). The most-studied condition is Glomerulonephritis Rapidly Progressive.
What health systems spend on Cyclophosphamid
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Cyclophosphamid works
All drug targets →- B-cell acute lymphoblastic leukemiaPhase 3
- B-cell chronic lymphocytic leukemiaPhase 3
- Behcet diseasePhase 3
- Ewing sarcomaPhase 3
- IgA glomerulonephritisPhase 3
- Richter transformationPhase 3
- T-cell acute lymphoblastic leukemiaPhase 3
- T-cell non-Hodgkin lymphomaPhase 3
- T-lymphoblastic lymphomaPhase 3
- ThrombocytopeniaPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1200796, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7154, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Cyclophosphamid
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 7 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Cyclophosphamid
- ChEMBL
- CHEMBL1200796
- PubChem CID
- 22420
- CAS number
- 6055-19-2
- FDA UNII
- 8N3DW7272P
- Wikidata
- Q27106287
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Cyclophosphamid
10 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Cyclophosphamid
23 conditionsAll 23 conditions
| Condition (as registered) | Trials |
|---|---|
| Glomerulonephritis Rapidly Progressive | 1 |
| Breast Cancer | 1 |
| Breast Carcinoma | 1 |
| Breast Cancer Metastatic | 1 |
| Breast Cancer Triple Negative | 1 |
| Stomach Cancer | 1 |
| Stomach Cancer Recurrent | 1 |
| Stomach Cancer, Adenocarcinoma | 1 |
| Esophageal Cancer | 1 |
| HER2-negative Breast Cancer | 1 |
| Neoadjuvant Chemotherapy | 1 |
| Clear Cell Renal Cell Carcinoma | 1 |
| Diffuse Large B-Cell Lymphoma (DLBCL) | 1 |
| Advanced NSCLC | 1 |
| Metastatic Colorectal Cancer | 1 |
| Prostate Cancer Metastatic | 1 |
| Prostate Cancer Locally Advanced | 1 |
| High-Risk Neuroblastoma | 1 |
| Patient With Insufficient Response Chemoimmunotherapy | 1 |
| Acute Myeloid Leukemia in Remission | 1 |
| Myelodysplastic Syndromes | 1 |
| Chronic Myeloid Leukemia in Remission | 1 |
| Myeloproliferative Syndrome | 1 |
Sponsors
lead sponsor per trialBy country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Cyclophosphamid trials
How many clinical trials are testing Cyclophosphamid?
10 current trials in our China, Germany, France, Spain, Italy, Sweden, Denmark, Switzerland, Czechia, Belgium, UK, Turkey, Netherlands, Austria, Norway, Australia and Israel registers name Cyclophosphamid as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Cyclophosphamid trials recruiting patients?
Yes. 9 of the 10 trials are recruiting: 5 with sites in China, 3 with sites in Germany, 2 with sites in France, 2 with sites in Spain, 2 with sites in Italy, 2 with sites in Sweden, 2 with sites in Denmark, 2 with sites in Switzerland, 2 with sites in Czechia, 2 with sites in Belgium, 1 with sites in UK, 1 with sites in Turkey, 1 with sites in Netherlands, 1 with sites in Austria, 1 with sites in Norway, 1 with sites in Australia and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Cyclophosphamid clinical trials?
Essen Biotech (2), Hangzhou Huasai Biomedicine Co., Ltd (2), Alentis Therapeutics AG (1) and Second Affiliated Hospital, Zhejiang University, School of Medicine (1), among 8 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Cyclophosphamid works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Cyclophosphamid works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Cyclophosphamid (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.